Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth reports “strong performance” in financial results

Wyeth reports “strong performance” in financial results

24th July 2009

Wyeth delivered a “strong performance” during the first six months of 2009, it has been asserted.

Bernard Poussot, chairman, president and chief executive of the organisation, made the comments as the firm released its financial results for the second quarter and first half of 2009 ended June 30th.

He said that the results reflect the ongoing strength of the company’s vaccine franchises Prevnar and Enbrel, as well as its nutritional products.

Mr Poussot noted that diluted earning per share, excluding certain significant items, increased by a total of eight per cent.

“Based on this outcome we are raising full-year earnings guidance. We remain focused on delivering strong performance as we work with Pfizer toward the successful integration of our two companies,” he concluded.

At the company’s annual meeting of stockholders, which took place earlier this month, the firm announced that its shareholders “overwhelmingly” approved the adoption of Wyeth’s merger agreement with Pfizer.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.